The diagnosis of the non-small cell lung cancer (NSCLC) is rather often made in state of advanced disease in the Czech Republic. We bring the information how in the Czech Republic are used the drugs specified for the I.
Line treatment requiring exact morphological diagnosis as well as molecular-genetic examination